PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.
The nanopore ZMW can enable lower starting amounts of DNA for PacBio sequencing, and may eventually enable direct RNA sequencing.
PacBio has released new software, which has increased read lengths and throughput, and aims to launch a new sample prep protocol and chemistry this year.
Although PacBio's product and services revenues were up 17 percent, total revenues declined 3 percent due to a lack of contractual revenue in the quarter.
The company aims to commercialize a sequencing instrument based on Helicos' technology and has secured orders from a Shanghai-based genomics startup.
The firms plan to focus on sample processing methods, workflow automation, algorithms, and database construction.
Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million.
PacBio alleged in its suit that Oxford Nanopore is infringing on a patent it holds related to single-molecule nanopore sequencing.
PacBio recently launched a new sequencing chemistry for Sequel that increases read lengths, and plans to double the platform's throughput by the end of the year.
Pacific Biosciences nearly doubled its product and services revenue due to sales of its Sequel instrument.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.